Table 1.

Characteristics of the studies included in the review.

References	Design	Country	Population	Age	Male/Female	Followed-up	Groups(N)
Montoya et al. (11)	Phase II RCT	Philippines	PPD-positive 3–10 mm;	18–45 years	38/142	6 months	M72/AS01B(N = 40) M72/AS01E(N = 40) M72/AS01E(N = 40) M72/AS02D(N = 40) M72/Saline(N = 10) AS01B alone(N = 10)
Thacher et al. (13)	Phase I/II RCT	Switzerland	HIV+ on cART;	18–50 years	26/11	6 months	M72/AS01E(N = 22) AS01 alone(N = 8) Saline(N = 7)
Idoko et al. (14)	Phase II RCT	Gambia	BCG-vaccinated infants;	2–7 months	159/141	6 months	Dose-outside EPI 1 dose M72/AS01E (N = 50) 2 doses M72/AS01E (N = 50) control(N = 50) Dose-within EPI 1 dose M72/AS01E (N = 52) 2 dosesM72/AS01E (N = 49) EPI only (N = 49)
Penn-Nicholson et al. (12)	Phase II RCT	South Africa	HIV-negative adolescents;	13–17 years	31/29	6 months	M72/AS01E(N = 80) Saline(N = 38)
Kumarasamy et al. (15)	Phase II RCT	India	QFT negative or positive;	18–59 years	167/73	12 months	ART-stable M72/AS01E (N = 40) Saline(N = 40) ART-naive M72/AS01E (N = 40) Saline(N = 40) HIV-ve M72/AS01E (N = 40) Saline(N = 40)
Gillard et al. (16)	Phase II RCT	Taiwan Estonia	Confirmed pulmonary TB; Treated pulmonary TB; No active pulmonary disease;	18–59 years	82/60	6 months	M72/AS01E (N = 71) Saline (N = 71)
Meeren et al. (17)	Phase IIb RCT	Kenya South Africa Zambia	Healthy; Stable chronic medical conditions;	18–50 years	2044/1529	3 years	M72/AS01E (N = 1786) Saline (N = 1787)

RCT, randomized controlled trial; PPD, tuberculin purified protein derivative; BCG, Bacillus Calmette–Guerin; HIV, human immunodeficiency virus; TB, tuberculosis; cART, combination anti-retroviral therapy; QTF, QuantiFERON Gold In-Tube test.